Knight Therapeutics, Inc. · TSX:GUD
Knight Therapeutics — Q2 2025 Earnings Presentation
21 slides from Knight Therapeutics's earnings presentation, Aug 7, 2025
Slide 1: Knight Therapeutics Inc. (TSX: GUD)
Building a leading specialty pharmaceutical company Knight Therapeutics Inc. (TSX: GUD) Investor presentation 1 June 2025
Slide 2: Forward Looking Statements
Forward Looking Statements This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated
Slide 3: Knight Overview
Knight Overview Knight is a multinational specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for Canada and Latin America with over 150 products and over 20 partners • Since founding in February 2014 – Raised $685M at increasing valuations ($3.50
Slide 4: Our Growth Strategies
Our Growth Strategies 1 In-license late-stage prescription pharmaceuticals Product 2 Acquire mature or “under-promoted” products from Big Pharma Portfolio 3 Develop near-term, low risk / low expense products Knight’s involvement Regulatory Market Sales and Discovery Pre-Clinical Clinical Trials Appr
Slide 5: Our Footprint
Our Footprint Adjusted Revenue1,2 by Geography ~ $373M in Revenue1 ~ $368M in Adjusted Revenue1,2 Rest of LATAM and Other Canada 14% 11 Countries 8% + distributors in Central America and Caribbean MEX 5% BR 48% ARG 11% +850 Employees COL 14% +150 Products 3 Headcount by Geography 23 Pipeline Product
Slide 6: Paladin and Sumitomo Transactions
Paladin and Sumitomo Transactions Transactions will place Knight Canada to top revenue contributor in 2 years Paladin Transaction Sumitomo Transaction • Asset purchase agreement to acquire Paladin for • Knight entered into exclusive license and supply $100M, plus $22M of inventory agreements with Su
Slide 7: Our Market
Our Market Pan-American (ex US) market represents ~6% of global pharmaceutical market Market Size at Constant Currencies¹ 100 % 16 80 GR CA Product Portfolio 60 Billion $ R 9% 92.2 CAG 40 R 14% CAG 74.3 66.8 60.1 51.5 47.7 10% 43.5 20 CAGR 39.4 39.8 34.4 33.9 36.3 3 17% 29.9 CAGR 23.6 26.5 15.4 16.2
Slide 8: Our Portfolio
Our Portfolio Innovative Promoted products: 76% of TTM Q1-2025 sales, delivered growth of 13% & 3-year CAGR of 28% ADJUSTED REVENUE1,2 BY KEY PRODUCTS PRODUCT PORTFOLIO Oncology and Hematology BGx 13% Innovative 87% Infectious Diseases ADJUSTED REVENUE1,2 BY THERAPEUTIC AREA Neurology & Neurology an
Slide 9: Pipeline and Products in Early Launch Stage
Pipeline and Products in Early Launch Stage Building for long-term growth over $200M peak potential sales LAUNCH / TERRITORY EXPECTED PRODUCT CA BR CO MX AR LAUNCH YEAR Oncology/Hematology Minjuvi® (DLBCL)1 Q1-24 ● Q1-25 ● 2025-2026 Minjuvi® (FL)2 ▲ ▲ ▲ ▲ 2027 Pemazyre® ■ ● ■ ● 2025-2026 Tavalisse®
Slide 10: Our Partners
. Our Partners AstraZeneca? (J GILEAD (Il Bristol Myers Squibb’ DB) onsen mc2 therapeutics & Sumitomo Pharma an Collegium. TherapeuticsMD PHARMACEUTICA at HET SINN (basilea) @: Debiopharm PHARMACEUTICA iopharmaceuticals io up ernuSs® nae! Tarneal permus Knight 10
Slide 11: Financial Highlights
Financial Highlights Innovative Promoted products: 76% of TTM Q1-2025 sales, delivered growth of 13% & 3-year CAGR of 28% Adjusted Revenue¹ by Therapeutic Area 400 2025 Guidance 2 16% GR ---------------------------------------------------- CA 300 Revenues of $390M-$405M CAD $ millions 200 Knight acq
Slide 12: Financial Highlights
Financial Highlights Strong Adjusted EBITDA1 and Operating Cash flows — Investing in Pipeline Adjusted EBITDA¹ and Cash Flow from Operations 70 60 2025 Guidance ---------------------------------------------------- 50 Adjusted EBITDA1 of ~13% of revenues 40 CAD$ in millions 30 Knight acquires GBT 20
Slide 13: Balance Sheet Highlights
Balance Sheet Highlights As at March 31, 2025 Post Paladin/Sumitomo Capital deployed in Q2: $141.5 M $126.9 M $132 M --------------------------------------- $47.0 M ------------------------------------------ Cash and --------------------------------------- --------------------------------------- • P
Slide 14: Strategic Fund Investments
Strategic Fund Investments FUND PERFORMANCE1 Fund investments • Invested to obtain preferential access to innovative products for Canadian market • Financial returns have been attractive, but have not been as effective at generating product leads • No longer investing into funds, beyond already comm
Slide 15: Capital Allocation
Capital Allocation Over $250M invested in NCIB or 31% of shares outstanding* Capital Allocation 300 Knight acquires Biotoscana end of 2019 2025 Acquisition ------------------------------------------------ 250 Closed Paladin and Sumitomo transactions in Canada in June 2025 200 CAD$ in millions 150 10
Slide 16: Capital Structure
Capital Structure As at June 16, 2025 $599.8 M $378.4 M 6.7x ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- 1 Market Capitalization Adjusted Enterprise Adjusted EBITDA Value2 Multiple3 99.
Slide 17: Management Team
Management Team Monica Percario - Brazil Samira Sakhia - Canada Global VP Regulatory and Quality President and Chief Executive Officer Sanofi, Head of Regulatory and Center of Expertise LATAM Paladin Labs, Chief Financial Officer Farmasa (now Hypera Pharma), Regulatory Affairs Executed sale of Palad
Slide 18: Board of Directors
Board of Directors Jonathan Ross Goodman Robert N. Lande Executive Chairman Paladin Labs, Board member from 1995 to 2014 Knight Therapeutics, Founder Stratos Global International LLC, President Paladin Labs, Co-founder, former President & CEO Michael J. Tremblay Former President of Astellas Canada J
Slide 19: Key Achievements - last 12 months
Key Achievements - last 12 months Performance New Products ---------------------------------------- TTM - Q1-25 • Acquired Paladin assets ------------------------------------------ • Licensed Sumitomo Canada assets • Revenue of $373M • Jornay PMTM for Canada and Latin • Adjusted Revenue1 of $368M Am
Slide 20: Why Knight – Great value in growing markets
Why Knight – Great value in growing markets Unique Platform in high growth Profitable Business with strong Strong Financial Position markets Revenues, Adj. EBITDA and Cashflow TTM Revenues TTM Adj. EBITDA +6% vs PY +2% vs PY Expanding Pipeline Experienced Management Team Strong Proven Track Record D
Slide 21: Knight Therapeutics Inc. (TSX: GUD)
Building a leading specialty pharmaceutical company Knight Therapeutics Inc. (TSX: GUD) Investor presentation 21 June 2025